Eli Lilly Slides as GLP-1 Coverage Concerns Likely Weigh on Sentiment

Eli Lilly and Company (LLY) is down 3.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be renewed concern about insurance coverage for obesity drugs, which is central to long-term demand for Zepbound and Lilly’s newer oral product, Foundayo. This could also be because investors took profits after a strong run, especially with no fresh company-specific negative filing or guidance cut apparent today.

Details:

A newly discussed employer-benefits survey showed some companies are becoming more selective on GLP-1 coverage for weight management, reinforcing worries that payer limits could slow volume growth.

Separately, PepsiCo employees were told certain weight-loss drugs would no longer be covered under the company health plan later this year, adding to concerns about employer pushback on cost.

Lilly’s own recent second-quarter update was fundamentally strong, with higher revenue, higher earnings, and raised full-year revenue guidance, which suggests today’s decline is more about sentiment and reimbursement risk than a deterioration in recent operating results.

The stock had also been trading near elevated levels after strong obesity and diabetes momentum, so a negative read-through on coverage may have prompted a sharper-than-sector pullback.

Sources:

Eli Lilly and Company, Business Group on Health, Bloomberg Law

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LLY Insider Trading Activity

$LLY insiders have traded $LLY stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:

PATRIK JONSSON (EVP & President, LLY Int'l) sold 6,500 shares for an estimated $7,638,149
ANAT HAKIM (EVP, GC & Secretary) sold 5,000 shares for an estimated $5,950,000
ILYA YUFFA (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares for an estimated $2,876,925
DONALD A ZAKROWSKI (SVP, Finance, & CAO) sold 2,000 shares for an estimated $2,370,020

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive LLY Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$LLY Hedge Fund Activity

We have seen 2,571 institutional investors add shares of $LLY stock to their portfolio, and 1,712 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 12,598,524 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,111,047,641
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 6,001,955 shares (+inf%) to their portfolio in Q2 2026, for an estimated $7,198,924,885
CAPITAL RESEARCH GLOBAL INVESTORS removed 3,759,507 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $4,509,265,481
WELLINGTON MANAGEMENT GROUP LLP removed 2,428,108 shares (-18.1%) from their portfolio in Q2 2026, for an estimated $2,912,345,578
FMR LLC added 2,121,444 shares (+8.1%) to their portfolio in Q2 2026, for an estimated $2,544,523,576
LILLY ENDOWMENT INC removed 1,520,000 shares (-1.7%) from their portfolio in Q2 2026, for an estimated $1,823,133,600
SG AMERICAS SECURITIES, LLC added 1,331,427 shares (+204.1%) to their portfolio in Q2 2026, for an estimated $1,596,953,486

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$LLY Congressional Stock Trading

Members of Congress have traded $LLY stock 10 times in the past 6 months. Of those trades, 5 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:

REPRESENTATIVE DAN NEWHOUSE sold up to $15,000 on 07/10.
REPRESENTATIVE MICHAEL A. RULLI sold up to $15,000 on 07/01.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $115,000 on 06/10, 04/14 and 1 sale worth up to $15,000 on 03/13.
REPRESENTATIVE LIZZIE FLETCHER sold up to $15,000 on 04/08.
REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 2 purchases worth up to $30,000 on 04/02 and 0 sales.
SENATOR ALAN ARMSTRONG sold up to $15,000 on 03/27.
REPRESENTATIVE DAVID TAYLOR purchased up to $15,000 on 02/26.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$LLY Price Targets

Multiple analysts have issued price targets for $LLY recently. We have seen 12 analysts offer price targets for $LLY in the last 6 months, with a median target of $1348.5.

Here are some recent targets:

Trung Huynh from RBC Capital set a target price of $1500.0 on 07/08/2026
Terence Flynn from Morgan Stanley set a target price of $1347.0 on 07/08/2026
Robyn Karnauskas from Truist Securities set a target price of $1370.0 on 07/08/2026
Chris Schott from JP Morgan set a target price of $1400.0 on 07/07/2026
Carter Gould from Cantor Fitzgerald set a target price of $1350.0 on 07/06/2026
David Risinger from Leerink Partners set a target price of $1232.0 on 06/25/2026
Akash Tewari from Jefferies set a target price of $1350.0 on 06/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.